neurotoxicity Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting neurotoxicity clinical trials across 5 countries. Studies span Not Applicable, Phase 4, Phase 2. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, Saint-Etienne, France. Updated daily from ClinicalTrials.gov.


neurotoxicity Trials at a Glance

7 actively recruiting trials for neurotoxicity are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Boston, Houston, and Saint-Etienne. Lead sponsors running neurotoxicity studies include Centre Hospitalier Universitaire de Saint Etienne, Ka-Wai Ho, and Australasian Gastro-Intestinal Trials Group.

Browse neurotoxicity trials by phase

Treatments under study

About neurotoxicity Clinical Trials

Looking for clinical trials for neurotoxicity? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new neurotoxicity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about neurotoxicity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

NeuropathyPeripheral NeuropathyPeripheral Neuropathy Due to Chemotherapy+1 more
Ka-Wai Ho60 enrolled2 locationsNCT07095998
Recruiting

A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity

neurotoxicity
M.D. Anderson Cancer Center100 enrolled1 locationNCT06144151
Recruiting
Not Applicable

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

LymphomaMyelomaCytokine Release Syndrome+1 more
University of Utah40 enrolled1 locationNCT07390071
Recruiting
Phase 4

Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome

Immune Effector Cell Associated Neurotoxicity Syndrome
Centre Hospitalier Universitaire de Saint Etienne60 enrolled1 locationNCT06706102
Recruiting
Phase 4

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations

neurotoxicityLiver TransplantationTremor+2 more
University of British Columbia124 enrolled1 locationNCT05089604
Recruiting

Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

Immune Effector Cell Associated Neurotoxicity Syndrome
zhang shoulong50 enrolled1 locationNCT05643092
Recruiting
Phase 2

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer
Australasian Gastro-Intestinal Trials Group100 enrolled10 locationsACTRN12619000566134